Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2011-04-12
2011-04-12
Shafer, Shulamith H (Department: 1647)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C424S093100, C424S093400, C426S002000, C426S071000, C426S029000, C426S004000
Reexamination Certificate
active
07923000
ABSTRACT:
Novel methods of determining efficacy of a treatment of inflammatory diseases of the bowel in mammals are provided. The methods are of use in screening and determining the efficacy of treatments of inflammatory diseases of the bowel, and for determining the efficacy response of individual sufferers of inflammatory diseases of the bowel to a given regime. Kits for carrying out the method are also provided.
REFERENCES:
patent: 5853697 (1998-12-01), Strober et al.
patent: 2005/0106133 (2005-05-01), Zink et al.
patent: 0508701 (1992-10-01), None
patent: 0862863 (1998-09-01), None
patent: 1312667 (2003-05-01), None
patent: WO 94/04180 (1994-03-01), None
patent: WO 94/04180 (1994-03-01), None
patent: WO 00/41707 (2000-07-01), None
patent: WO 00/42168 (2000-07-01), None
patent: WO 02/083879 (2002-10-01), None
patent: WO 03/010297 (2003-02-01), None
patent: WO 03/010298 (2003-02-01), None
patent: WO 03/010299 (2003-02-01), None
Papadakis et al. 2000. Ann Rev Med. 51:289-298.
Vignali DAA. 2000. Journal of Immunological Methods 243:243-255.
Thompson et al 1999. Gut. 45/Suppl II:II43-II47.
Whiteside 2003. Chapter 61 in The Cytokine Handbook, vol. II, 4th edition (pp. 1384-1386 enclosed).
www.invitrogen.com/content.cfm?pageid+11317&CID=KNC-GOOGLE&s—kwcid=..., downloaded May 20, 2007.
Togawa et al. 2002 Am J. Physiol, Gastrointestinal Liver Physiol 283:G187-G195.
Blumberg et al. 1999. Current Opinion in Immunology 11:648-656.
Vilcek 2003. Chapter 1 in “The Cytokine Handbook” vol. I, 4thedition (p. 6, enclosed).
Bing et al. 1998. World J Gastroenterology 4:252-255.
O'Gorman et al. 2008. Handbook of Human Immunology, 2nd edition, pp. 154 and 155.
Hart et al. 2003. J. Clin Gastroent 36:111-9).
Grundmann et al. 2010. J. Gastroenterology and Hepatology 25:691-699.
Stallmach et al., “Induction and Modulation of Gastrointestinal Inflammation”, Trends Immunology Today, Oct. 1998, vol. 19 No. 10 pp. 438-441.
Marteau et al., “Potential of Using Lactic Acid Bacteria for Therapy and Immnunomodulation in Man”, FEMS Microbiology Reviews 12 (1993) 207-220.
Fergus Shanahan, “The Intestinal Immune System”, Physiology of the Gastroinestinal Tract, Third Edition, 1994.
Schmitt et al., “The Immunostimulatory Function of IL-12 in T-Helper-Cell Development and Its Regulation by TGF-B, IFN-y and IL-4”,Chem Immunet Basel Karger, 1997, vol. 68, pp. 70-85.
Panwala et al., “A Novel Model of Inflammatory Bowel Disease: Mice Deficient for the Multiple Drug Resistance Gene, mdrla, Spontaneously Develop Colitis”, The American Association of Immunologists, 1998, The Journal of Immunology, 1998 161: 5733-5744.
O'Mahony et al., “Probiotic Impact on Microbial Flora, Inflammation and Tumour Development in IL-10 Knockout Mice”, Aliment Pharmacol Ther 2001: 15: 1219-1225.
Medaglini et al., “Mucosal and Systemic Immune Responses to a Recombinant Protein Expressed on the Surface of the Oral Commensal Bacterium Streptococcus gordonii after oral colonization”, Proc. Natl. Acad. Sci. USA vol. 92, pp. 6868-6872, Jul. 1995 Medical Sciences.
Charteris et al, “Antiobiotic Sysceptibility of Potentially Probiotic Bifidobacterium Isolates From the Human Gastrointestinal Tract”, Letters in Applied Microbiology 1998, 26, 333-337.
McGee et al., “A Synergistic Relationship Between TNF-x, IL-1B, and TGF-B1 on IL-6 Secretion by the IEC-6 Intestinal Epithelial Cell Line”, Immunology 1995 86 6-11.
Bouhnik et al., “Effects of Bifidobacterium SP Fermented Milk Ingested With or Without Inulin on Colonic Bifidobacteria and Enezymatic activities in Healthy Humans” European Journal of Clinical Nutrition (1996) 50, 269-273.
Charteris et al., “Development and application of an In Vitro Methodology to Determine the Transit Tolerance of Potentially ProbioticLactobacillusandBifidobacteriumSpecies in the Upper Human Gastrointestinal Tract” Journal of Applied Microbiology 1998, 84, 759-768-XP 000929203.
Charteris et al., “Antiobiotic Susceptibility of Potentially ProbioticBifidobacteriumIsolates from the Human Gastrointestinal Tract, ”Letters of Applied Microbiology 1998, 26, 333-337.
Charteris et al., “Selective Detection, Enumeration and Identification of Potentially ProbioticLactobacillusandBifidobacteriumSpecies in Mixed Bacterial Populations”, International Journal of Food Microbiology 35 (1997) 1-27.
Chevalier et al., “Detection ofBifidobacteriumSpecies by Enzymatic Methods”, Journal of Applied Basteriology 1990, 68, 619-624.
Collins et al., “Selection of Problotic Strains for Human Applications”, In. Dairy Journal 8 (1998) 487-490.
Gibson et al., “Dietary Modulation of the Human Gut Microflora Using Prebiotics”, Journal of Nutrition, (1998) 80. Suppl. 2 S209-S212.
Charteris et al., “Effect of Conjugated Bile Salts on Antibiotic Susceptibility of Bile Salt-TolerantLactobacillusandBifidobacteriumIsolates”, Journal of Food Protection vol. 63, No. 10, 2000, pp. 1369-1376.
Groux et al., “Regulatory T Cells and Inflammatory Bowel Disease”, Viewpoint Immunology Today Oct. 1999.
Brandtzaeg et al., “Immunopathology of Human Inflammatory Bowel Disease”, Springer Seminars in Immunopathology (1997) 18: 555-589.
Chauviere et al., Adhension of HumanLactobacillus AcidophilusStrain LB to Human Enterocyte-like Caco-2 Cells, Journal of General Microbiology (1992), 138,1689-1696.
Cicco et al., “Inducible Production of Interleukin-6 by Human Polymorphonuclear Neutrophils: Role of Granulocyte-Macrophage Cology-Stimulating Factor and Tumor Necrosis Factor-Alpha”, 1990 The American Society of Hematology, Blood, vol. 75, No. 10 (May 15) 1990: pp. 2049-2052.
Donnelly et al., “Differential Regulation of II-1 Production in Human Monocytes by IFN-y and IL-4” , The Journal of Immunology, vol. 145, 569-575. No. 2 Jul. 15, 1990.
Favier et al., Fecal B-D-Galactosidase Production and Bifidobacteria Are Decreased in Crohn's Disease, Digestive Diseases and Sciences, vol. 42, No. 4 (Apr. 1997), pp. 817-822.
Monteleone et al., “Manipulation of Cytokines in the Management of Patients With Inflammatory Bowel Disease”, Ann Med. Nov. 2000:32(8):552-60.
Rogler et al., “Cytokines in Inflammatory Bowel Disease”, World J Surg (1998) 22:382-9.
Strober et al., “Reciprocal IFN-gamma and TGF-Beta Responses Regulate the Occurrence of Mucosal Inflammation”, Immunol Today. Feb. 1997;18(2):61-4.
Chadwick et al.“Activation of the Mucosal Immune System in Irritable Bowel Syndrome”, Gastroenterology (2002) 122:1778-83.
Anand et al.“Cytokines and Inflammatory Bowel Disease”, Tropical Gastroenterology. 1999; 20(3):97-106.
Gasche et al., “IL-10 Secretion and Sensitivity in Normal Human Intestine and inflammatory Bowel Disease”, Journal of Clinical Immunology vol. 20, No. 5, 2000.
Hommes et al., “Anti- and Proinflammatory Cytokines in the Pathogenesis of Tissue Damage in Crohn's Disease”, 2000 Lippincott Williams and Wilkins 1363-1950.
McKay et al., “Review article: In Vitro Models in Inflammatory Bowel Disease”, Aliment Pharmacol Ther 1997: 11 (Suppl. 3): 70-80.
L. Lakatos, “Immunology of Inflammatory Bowel Diseases”, Acta Physiologica Hungarica, vol. 87 (4), pp. 355-372 (2000).
Powrie et al., Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease in Scid Mice Reconstituted with CD45Rbhi CD4+ T Cells, Immunity vol. 1, 553-562, Oct. 1994.
Van Damme et al., “The Proportion of Th1 Cells Which Prevail in Gut Mucosa, is Decreased in Inflammatory Bowel Syndrome”, Clin Exp Immunol 2001: 125:383-390.
McBrearty, S., et al. “Probiotic Bifidobacteria and Their Identification Using Molecular Genetic Techniques,” Teagasc, Dairy Products Research Centre, Moorepark, Fermoy, Co. Cork, Ireland, Department of Microbiology, University College Cork,
Chen Ker-Sang
Collins John Kevin
Kiely Barry Pius
Luo Fangyi
O'Mahony Liam Diarmuid
Clay Cynthia L.
Kim William Zerby
Shafer Shulamith H
The Procter & Gamble & Company
LandOfFree
Methods of determining efficacy of treatments of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of determining efficacy of treatments of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of determining efficacy of treatments of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2689577